Sorted By Test Name - Mayo Medical Laboratories

FFTRC
91091
TRZ
9624
Useful For: Identifying the presence of a TACI mutation in a symptomatic patient when the mutation
has been identified in an affected family member
Interpretation: An interpretive report will be provided that describes the presence or absence of the
previously identified mutation(s), and their potential clinical significance. Variants of unknown clinical
significance within the specific exon being evaluated also will be documented in the report.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Mackay F, Ambrose C: The TNF family members BAFF and APRIL: the
growing complexity. Cytokine Growth Factor Rev 2003;14:311-324 2. Castigli E, Geha RS: Molecular
basis of common variable immunodeficiency. J Allergy Clin Immunol 2006;117:740-746 3. Castigli E,
Wilson SA, Garibyan L, et al: TACI is mutant in common variable immunodeficiency and IgA
deficiency. Nat Genet 2005;37(8):829-834 4. Salzar U, Chapel HM, Webster ADB, et al: Mutations in
TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat
Genet 2005;37(8):820-828 5. Castigli E, Wilson S, Garibyan L, et al: Reexamining the role of TACI
coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet
2007;39(4):429-431
Tranylcypromine (Parnate)
Reference Values:
Reference Range: 10.0 – 100.0 ng/mL
Test Performed By:
Medtox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
Trazodone, Serum
Clinical Information: Trazodone is indicated for treatment of depression characterized by a
prominent and persistent dysphoric mood that interferes with daily function. Trazodone is administered in
oral doses of 150 to 400 mg/day in divided doses to yield blood levels of 500 to 1,100 ng/mL that
correlate with response to the drug. Within the therapeutic range, trazodone is 93% protein bound. It
exhibits a volume of distribution of 1.0 L/kg and an elimination half-life of 6 hours. Oral bioavailability
ranges from 60% to 90%. Priapism and hypotension are side effects that occur at therapeutic doses of the
drug. There are no known major drug interactions that affect the pharmacology of trazodone. Toxicity is
characterized by respiratory arrest, seizure, and electrocardiogram changes typical of atrioventricular
conduction block. There is no specific antidote to trazodone overdose; treatment is symptomatic and
supportive.
Useful For: Monitoring for optimal therapeutic concentrations Monitoring patient compliance
Interpretation: Optimal response to trazodone is observed when serum levels are in the range of 500
to 1,100 ng/mL.
Reference Values:
Therapeutic concentration: 500-1,100 ng/mL
Clinical References: Monteleone P, Gnocchi G, Delrio G: Plasma trazodone concentrations and
clinical response in elderly depressed patients: a preliminary study. J Clin Psychopharmacol
1989;9:284-287
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1780